NYSE:KDMN - Kadmon Stock Price, Forecast & News

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Kadmon Holdings Inc (NYSE:KDMN) announced its quarterly earnings results on Thursday, August, 9th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.50. The company had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.90 million. Kadmon had a negative return on equity of 188.03% and a negative net margin of 9,855.14%. View Kadmon's Earnings History.

Kadmon is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Kadmon.

4 brokers have issued 12 month price objectives for Kadmon's stock. Their forecasts range from $6.00 to $25.00. On average, they expect Kadmon's stock price to reach $12.75 in the next twelve months. This suggests a possible upside of 185.9% from the stock's current price. View Analyst Price Targets for Kadmon.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kadmon.

News stories about KDMN stock have been trending extremely negative this week, InfoTrie reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Kadmon earned a media sentiment score of -4.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Kadmon.

Some companies that are related to Kadmon include Principia Biopharma (PRNB), Ra Pharmaceuticals (RARX), Synthorx (THOR), Aurinia Pharmaceuticals (AUPH), Forty Seven (FTSV), Cambrex (CBM), Karuna Therapeutics (KRTX), Epizyme (EPZM), Prestige Consumer Healthcare (PBH), Pacira Biosciences (PCRX), Turning Point Therapeutics (TPTX), Xencor (XNCR), Ligand Pharmaceuticals (LGND), Eidos Therapeutics (EIDX) and Ironwood Pharmaceuticals (IRWD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Iovance Biotherapeutics (IOVA), Applied Materials (AMAT), Biocept (BIOC), Bristol-Myers Squibb (BMY), Global Blood Therapeutics (GBT), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM) and Catalyst Pharmaceuticals (CPRX).

(KDMN) raised $101 million in an initial public offering (IPO) on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Kadmon's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (11.29%), Boxer Capital LLC (4.79%), State Street Corp (2.67%), Sofinnova Investments Inc. (1.83%), Geode Capital Management LLC (1.45%) and Schonfeld Strategic Advisors LLC (0.73%). View Institutional Ownership Trends for Kadmon.

KDMN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Goldman Sachs Group Inc., Quantitative Systematic Strategies LLC, Bank of America Corp DE, Algert Global LLC and Principal Financial Group Inc.. View Insider Buying and Selling for Kadmon.

KDMN stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Perceptive Advisors LLC, State Street Corp, Schonfeld Strategic Advisors LLC, EAM Global Investors LLC, Panagora Asset Management Inc., EAM Investors LLC and Credit Suisse AG. View Insider Buying and Selling for Kadmon.

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KDMN stock can currently be purchased for approximately $4.46.

Kadmon has a market capitalization of $578.42 million and generates $1.40 million in revenue each year. The company earns $-54,250,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Kadmon employs 116 workers across the globe.View Additional Information About Kadmon.

The official website for Kadmon is http://www.kadmon.com/.

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 212-308-6000 or via email at [email protected]